Recombinant CD19 (Inebilizumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA
Hôte: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits CD19 (Inebilizumab Biosimilar)
- CD19 (Inebilizumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp CD19 (Inebilizumab Biosimilar) est non-conjugé
-
Application
- ELISA
- Fonction
- Inebilizumab Biosimilar - Anti-CD19 mAb
- Attributs du produit
- Antibody Type: IgG1-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Classe de qualité
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- CD19 (Inebilizumab Biosimilar)
- Abstract
- CD19 (Inebilizumab Biosimilar) Produits
- Classe de substances
- Biosimilar
- Sujet
-
MEDI-551
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion. - Numéro CAS
- 1299440-37-1
-
Vous êtes ici:
